<DOC>
	<DOCNO>NCT02250807</DOCNO>
	<brief_summary>The purpose study show superiority simeprevir ( SMV ) combination sofosbuvir 12 week versus historical control . Historical control composite observe historical sustain virological response Week 12 ( SVR12 ) rate SMV combination ( pegylated ) interferon ( PegIFN ) /ribavirin ( RBV ) subpopulation study HPC3011 ( NCT01567735 ) depend percentage treatment-naive , prior relapser , prior non-responder , interferon ( IFN ) -intolerant subject enrol study .</brief_summary>
	<brief_title>Efficacy Safety Study Simeprevir Combination With Sofosbuvir Subjects With Chronic Genotype 4 Hepatitis C Virus Infection</brief_title>
	<detailed_description>This Phase 3 , open-label ( people know identity intervention ) , single-arm , multicenter study ( conduct multiple site ) . The study consist 3 period : Screening period ( 4 week ) , Treatment period ( 12 Weeks ) Post treatment follow-up period ( 24 week end treatment ) . The duration subject ' participation approximately 40 week . In treatment period subject receive oral capsule simeprevir along oral tablet sofosbuvir daily 12 week . Primarily efficacy evaluated percentage subject sustain virologic response Week 12 end treatment . Subjects ' safety monitor throughout study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Subjects confirm hepatitis C virus ( HCV ) HCV RNA great ( &gt; ) 10000 international unit per milliliter ( IU/mL ) Subjects treatment naive treatmentexperienced . Subjects must documentation liver biopsy fibroscan agree one screen Subjects cirrhosis must hepatic imaging procedure ( ultrasound , CT scan magnetic resonance image [ MRI ] ) within 6 month screen visit ( screening period ) find suspicious hepatocellular carcinoma ( HCC ) Women childbearing potential men female partner childbearing potential must agree use effective form contraception , heterosexually active , nonchildbearing potential Evidence clinical hepatic decompensation Any liver disease nonHCV etiology Subjects past history treatment approve investigational DAA Coinfection human immunodeficiency virus ( HIV ) type 1 type 2 ( HIV1 HIV2 ) ( positive HIV1 HIV2 antibodies test screen ) Infection/coinfection HCV nongenotype 4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Genotype 4 chronic hepatitis C</keyword>
	<keyword>Simeprevir</keyword>
	<keyword>Sofosbuvir</keyword>
</DOC>